Diane-35 + metformin + orlistat

A combination therapy consisting of Diane-35 (cyproterone acetate 2 mg and ethinylestradiol 35 µg), metformin, and orlistat. This triple therapy is used primarily for treating polycystic ovary syndrome (PCOS) in overweight or obese patients with insulin resistance. The combination addresses multiple aspects of PCOS: Diane-35 provides antiandrogenic effects and hormonal regulation, metformin improves insulin sensitivity, and orlistat aids in weight management through reduced fat absorption. Clinical studies show this combination is more effective than monotherapy in reducing androgens, improving metabolic parameters, and managing weight in PCOS patients.